systematic_review
2008
High Quality
Huperzine A for Alzheimer's disease (Cochrane review)
Li J, Wu HM, Zhou RL, Liu GJ, Dong BR
Published in Cochrane Database of Systematic Reviews
Methodology
Cochrane systematic review of randomised placebo-controlled trials of huperzine A in Alzheimer's disease
Key Findings
Included trials suggested benefit on cognition and activities of daily living, but methodological quality was poor and evidence was judged insufficient.
Conclusions
There is currently insufficient evidence of the effects of huperzine A for Alzheimer's disease.
Limitations
Small, poorly reported Chinese trials with high risk of bias.
Supplements Studied
Huperzine A
Compound
There is currently insufficient evidence of the effects of huperzine A for Alzheimer's disease.
Related Health Concerns
Study Details
Year:2008
Sample Size:474
Duration:12 weeks
Quality Score:9/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.